What Laprophan does

Laprophan is a Moroccan pharmaceutical laboratory founded in 1949 by Dr. Abderrahim Bennis, operating as a vertically integrated developer, manufacturer, and distributor of branded generic and innovative pharmaceutical products. The company operates 55,000 m² of GMP-certified manufacturing capacity across three Casablanca sites (headquarters, 20,000 m² industrial site, and 18,000 m² distribution center), employs 1,400 collaborators, and commercializes 1,000+ pharmaceutical SKUs across 8 therapeutic areas (anti-infectives, cardiovascular, neuropsychiatry, anesthesia and pain, anti-inflammatory and allergy, digestive and respiratory specialties, resuscitation and perfusion, and prevention). Its core technological differentiators are 5 patented products registered in 100+ countries: IXOR® (first buffered effervescent omeprazole PPI), DI-INDO® (indomethacin calcium pentahydrate), NEOFORTAN® (first musculotropic antispasmodic in effervescent form), and LEVAMOX® (first amoxicillin-clavulanic acid combination in effervescent tablets), alongside newer initiatives in blockchain drug traceability and AI-assisted clinical trials. The company also operates a camelid nanobody R&D platform through the IBYLTECH joint venture with MAScIR Foundation and UM6P.

Laprophan generates revenue through direct sales to pharmacies and hospitals across Morocco via an in-house sales force, complemented by export distribution to 50+ countries in Europe and Africa through partner distributors. International expansion is anchored by its Luxembourg-based Europhan platform, which executed the June 2026 acquisition of Swiss specialty pharmaceutical company Rivopharm (adding ~$100M annual revenue). Recent inorganic moves include acquisitions of Amanys Pharma (November 2023), AIF Pharma Maroc (February 2024), Botanic Pharma (June 2024, natural and cannabis-based supplements), and Rivopharm, alongside a strategic partnership with Sinopharm International to extend presence across African markets. The company holds partnerships with global pharmaceutical majors including Sanofi, Pfizer, Bristol Myers Squibb, Novo Nordisk, Baxter, and Danone, signaling its position as a contract manufacturing and distribution partner in the region.

In February 2023, Laprophan opened its capital to a $72 million (750 million MAD) minority equity investment led by Mediterrania Capital Partners alongside European development finance institutions (DEG, FMO, Proparco), marking its first institutional capital event and funding the subsequent acquisition-led expansion strategy. The company maintains dual NM ISO 9001 and NM ISO 13485 certifications, Coface Quality Label recognition, and was qualified as 'excellent' by the World Bank in a 1980 audit of Morocco's pharmaceutical sector. Laprophan remains privately held under the Bennis family (Dr. Farid Bennis as President, Reda Bennis as Vice-President), with no public listing.

Name

Laprophan

Legal name

Laprophan

Website

https://laprophan.com

Company type

Private

Founded year

1949

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Laprophan is Morocco's pioneering pharmaceutical laboratory founded in 1949, developing, manufacturing, and distributing 1,000+ pharmaceutical products across 8 therapeutic areas for pharmacy, hospital, and export markets in 50+ countries, with 1,400 employees across three Casablanca sites.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)

akta.pro secondary industries

Specialty Care Pharmaceuticals (HLAIAAAB), Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)

Keywords

• Pharmaceutical manufacturing
• Generic medicines
• Hospital pharmaceuticals
• Effervescent formulations
• Pharmaceutical distribution

Headquarters

HQ city

Casablanca

HQ country

Morocco

HQ region

Africa

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical product sales: Sale of branded generic and innovative pharmaceutical products across 1,000+ SKUs through pharmacy and hospital channels in Morocco and 50+ export countries. Revenue from direct product sales to pharmacies, hospital procurement, and distributor orders.

Go-to-market motion2 records

Distribution channels4 records

Marketing channels7 records

Core offering

Laprophan develops, manufactures, and commercializes branded generic and innovative pharmaceutical products across 8 therapeutic areas (anesthesia, anti-infectives, cardiovascular, neuropsychiatry, anti-inflammatory, digestive, resuscitation, and prevention), operating GMP-certified manufacturing in Casablanca and distributing 1,000+ SKUs through pharmacy channels, hospital procurement, and export distributors across 50+ countries. Its proprietary portfolio is anchored by four patented effervescent formulations (IXOR, DI-INDO, NEOFORTAN, LEVAMOX) and supplemented by hospital massive solutions, melatonin supplements, and acquired product lines from Amanys Pharma, Botanic Pharma, and Rivopharm.

Product overview

Laprophan is a Moroccan pharmaceutical laboratory founded in 1949, operating as a diversified pharmaceutical platform with over 1,000 commercialized SKUs across 50+ countries. The company offers a comprehensive portfolio organized around 8 therapeutic areas (anti-infectives, cardiovascular, neuropsychiatry, anesthesia, digestive, resuscitation, supplementation, and prevention), built around patented innovations including IXOR® (omeprazole effervescent PPI), DI-INDO® (indomethacin calcium pentahydrate), NEOFORTAN® (phloroglucinol antispasmodic), and LEVAMOX® (amoxicillin-clavulanic acid antibiotic), all featuring proprietary effervescent buffer formulations. The product line also includes melatonin supplements and hospital massive solutions for resuscitation. Recent acquisitions (Botanic Pharma, AIF Pharma, Amanys Pharma, Rivopharm) have expanded capabilities into natural dietary supplements, cannabis-based products, and European specialty pharmaceuticals.

Differentiator

Problem solved

Functional benefit

Brands

• IXOR: First buffered effervescent PPI (Omeprazole) for gastric pain relief
• DI-INDO
• NEOFORTAN
• LEVAMOX

Products and services

• IXOR (Omeprazole) First buffered effervescent proton pump inhibitor (PPI) providing immediate relief from gastric pain, sold to pharmacies, hospitals, and distributors in Morocco and export markets. Patented formulation registered in 100+ countries.
• DI-INDO (Indomethacin calcium pentahydrate) Patented calcium pentahydrate molecular form of indomethacin for anti-inflammatory treatment, sold through pharmacy and hospital channels.
• NEOFORTAN (Phloroglucinol) First musculotropic antispasmodic available in effervescent tablet form, providing rapid relief from smooth muscle spasms through an innovative galenic formulation.
• LEVAMOX (Amoxicillin + Clavulanic acid) First amoxicillin-clavulanic acid combination in effervescent tablet form, representing an innovative antibiotic formulation for enhanced patient compliance and efficacy.
• Mélatonine Laprophan 1.9 mg Melatonin-based dietary supplement positioned for sleep disorders in geriatrics, with ongoing research exploring post-operative pain relief and hair loss treatment applications.
• Hospital Massive Solutions Hospital fluids for resuscitation and perfusion, covering critical care needs in medical facilities across therapeutic areas including reanimation and perfusion services.

Quantifiable outcome

• 1,000+ pharmaceutical SKUs commercialized across 50+ countries
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature7 records

Partnerships

15 partnerships are on record, tiered core, minor and flagship.

• RivopharmcoreStrategic or Co-development Partner · 17 June 2026Laprophan completed the acquisition of a controlling stake in Rivopharm, a Switzerland-based specialty pharmaceutical company, through its Luxembourg-based European platform Europhan. This is Laprophan's first European acquisition, adding approximately $100 million in annual revenue and enabling a diversified international pharmaceutical platform spanning Europe, Africa, and the Middle East.
• St. Francis Hospital New YorkminorStrategic or Co-development Partner · 11 October 2025Laprophan participated in the 1st Marocco-American Medical Symposium in Laâyoune, co-organized with St. Francis Hospital in New York and the Faculty of Medicine of Laâyoune, promoting medical knowledge transfer and scientific dialogue between Moroccan and American healthcare professionals.
• AmCham Morocco (American Chamber of Commerce)minorGTM or Marketing Partner · 11 October 2025Laprophan was an official sponsor of the AmCham Morocco Annual Gala celebrating 240 years of Morocco-US friendship and 20 years of free trade, alongside OCP, Visa, Coca-Cola and Oulmès.
• GIZ (Gesellschaft für Internationale Zusammenarbeit)minorGTM or Marketing Partner · 19 June 2025Laprophan participated in the GIZ 50th anniversary ceremony at the German Ambassador's residence in Morocco, celebrating five decades of German-Moroccan development cooperation and reinforcing ties with German institutional partners.
• ANPMA (Agence Nationale des Plantes Médicinales et Aromatiques)coreStrategic or Co-development Partner · 26 November 2024Three-way public-private partnership signed on November 26, 2024 at ANPMA headquarters in Taounate, bringing together ANPMA, Université Sidi Mohamed Ben Abdellah (USMBA), and Laprophan. The agreement aims to promote R&D and innovation in plant-based dietary supplements, create new products for Moroccan and international markets, and strengthen local economy through sustainable use of natural resources.
• Université Sidi Mohamed Ben Abdellah (USMBA)coreStrategic or Co-development Partner · 26 November 2024Academic partner in the three-way R&D partnership with ANPMA and Laprophan for plant-based dietary supplement innovation. USMBA contributes scientific expertise and knowledge transfer to the private sector, with President Pr. Mustapha Ijjaali signing the agreement.
• Dar ZhorminorOthers · 13 November 2024Laprophan partnered with the Dar Zhor association for breast cancer awareness and support, including a solidarity race in November 2025 and employee sensitization sessions at the industrial unit, addressing screening, risk factors, and prevention.
• IBYLTECHcoreStrategic or Co-development Partner · 13 November 2024Joint venture entity created between Laprophan, MAScIR Foundation, and UM6P (Université Polytechnique Mohammed VI) for camelid nanobody research and development targeting cosmetic and medical applications. Named IBYLTECH (Ibyl = camel in Arabic, Tech = biomedical technology). Located at UM6P's Laâyoune campus.
• AHK Maroc (German Chamber of Commerce and Industry)minorGTM or Marketing Partner · 11 November 2024AHK Maroc delegation visited Laprophan's logistics center on November 11, 2024, with discussions on challenges in the pharmaceutical industry and potential Morocco-Germany collaboration opportunities. Led by Katharina Felgenhauer.
• Botanic PharmacoreStrategic or Co-development Partner · 25 June 2024Laprophan acquired a majority stake in Botanic Pharma, a natural dietary supplements company, in June 2024 (pending regulatory approval). Botanic Pharma holds certifications for cannabis-based product development in Morocco and brings capabilities in natural health solutions. The acquisition expands Laprophan's portfolio in Europe and Africa and adds R&D capacity for natural and cannabis-based health products.
• AIF Pharma MoroccocoreStrategic or Co-development Partner · 26 February 2024The Moroccan Competition Council approved Laprophan's exclusive takeover of AIF Pharma Morocco in February 2024, following acquisition of its entire share capital and voting rights. The transaction consolidated Laprophan's presence in the national market.
• Amanys Pharma (from SPE Capital and Proparco)coreStrategic or Co-development Partner · 10 November 2023Laprophan acquired Amanys Pharma from SPE Capital and Proparco in November 2023 (subject to regulatory approvals), forming a diversified pharmaceutical group in Morocco and Africa with specialized and complementary poles. SPE Capital and Proparco had supported Amanys Pharma's growth, industrial capacity expansion, and governance improvement since 2020.
• Sinopharm InternationalflagshipStrategic or Co-development Partner · 1 November 2023Laprophan and Sinopharm International signed strategic partnership agreements on November 1, 2023, witnessed by Minister of Industry and Commerce Ryad Mezzour, to extend their cooperation beyond Morocco into other African countries. This builds on existing collaboration including Sinopharm Foreign Trade agreements signed in February 2023. The partnership aims to develop new industrial synergies, joint health projects, and expand cooperation in pharmaceutical innovation across the African continent.
• MAScIR Foundation (Université Polytechnique Mohammed VI)flagshipStrategic or Co-development Partner · 2 October 2023Laprophan and MAScIR Foundation (affiliated with UM6P) signed a joint venture agreement on October 2, 2023 in Laâyoune, creating IBYLTECH (Ibyl = camel in Arabic, tech = biomedical technology). The JV focuses on developing nanobodies derived from camelids for cosmetic and medical indications, leveraging Morocco's unique camelid resources. Ceremony presided by Wali Abdeslam Bekrat with presence of Elisabeth Moreno.
• Université Mohammed VI des Sciences de la Santé (UM6SS)coreStrategic or Co-development Partner · 24 September 2023Laprophan partners with UM6SS on the 'Compétences Pratiques en Pharmacie' certified training program, unique in Morocco, which has trained over 1,200 pharmacy assistants across all regions. The program focuses on practical skills, appropriate medicine use, abuse prevention, and patient communication. Joint JPM (Journées Médico-Pharmaceutiques) events held in Dakhla (November 2025) and other locations.

Scale indicators10 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cooper Pharma: Cooper Pharma is one of the leading Moroccan pharmaceutical manufacturers, offering a broad generic and branded pharmaceutical portfolio distributed across Morocco, Francophone Africa, and the MENA region. It is a direct Moroccan competitor to Laprophan with overlapping therapeutic coverage and similar export-driven growth strategy.
• Sothema: Sothema (Société Thérapeutique Marocaine) is a top Moroccan pharmaceutical manufacturer producing generics, branded generics, and biosimilars for the Moroccan and African markets. It competes head-to-head with Laprophan in Moroccan tenders and African export channels.
• Galenica: Galenica is a Moroccan pharmaceutical manufacturer with a broad portfolio of generics, OTC products, and medical devices. It shares Laprophan's positioning as a domestic Moroccan producer with ambitions across African export markets.
• Pharma 5: Pharma 5 is a Moroccan pharmaceutical laboratory producing branded generics and OTC products, primarily serving Morocco and export markets in Francophone Africa. Its therapeutic breadth and Moroccan manufacturing base make it a direct comparator to Laprophan.

Broad incumbents

• Aspen Pharmacare: Aspen Pharmacare is Africa's largest pharmaceutical manufacturer with operations across South Africa, Europe, and Latin America, producing branded generics and specialty pharmaceuticals. It serves as the incumbent African pharma benchmark that Laprophan aspires to scale toward.
• Sanofi: Sanofi is a global pharmaceutical major with established operations across Africa and a recognized partner of Laprophan for distribution and licensing. It is a broad incumbent that competes in specialty and primary care categories where Laprophan also operates.

Regional players

• Medis (Tunisia): Medis is a leading Tunisian pharmaceutical manufacturer producing branded generics for Maghreb and African markets. It is a regional North African peer with comparable therapeutic coverage and Francophone Africa export focus.
• SAIDAL Group: SAIDAL is Algeria's flagship state-linked pharmaceutical manufacturer producing branded generics across therapeutic areas for domestic and African export markets. It is a North African regional peer with similar pharmaceutical-sovereignty positioning.
• Egyptian International Pharmaceutical Industries (EIPICO): EIPICO is one of the largest pharmaceutical manufacturers in Egypt and the MENA region, producing branded generics across therapeutic areas for domestic and Arab/African export markets. It is a North African/MENA regional peer in scale and category overlap.

Emerging players

• Cipla: Cipla is an Indian global pharmaceutical manufacturer with a strong Africa-focused generics portfolio and established distribution across the continent. It is a key emerging-market competitor that pressures Laprophan's African export pricing.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/laprophan-s-a-

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries5 records

Funding overview

Funding rounds1 record

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A2 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Laprophan